Heart Failure - Optimizing Therapy with Recently Approved Novel Agents
Cardiology
Curriculum:
Current and Emerging Treatment Options for Patients with Chronic Heart Failure
Current and Emerging Treatment Options for Patients with Chronic Heart Failure
Credits:
1.5 AMA PRA Category 1 Credit(s) ™
1.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 29, 2015
December 29, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Cardiologists; Primary Care Physicians; Hospitalists; Internal Medicine Physicians
Relevant Terms:
Chronic heart failure; heart failure
Gregg Fonarow, MD, FACC, FAHA
Gregg Fonarow, MD, FACC, FAHA
Professor of Medicine, Co-Chief
UCLA Division of Cardiology
Director, Ahmanson-UCLA Cardiomyophathy Center
Los Angeles, California
Bio
Gregg C. Fonarow, MD, FACC, FAHA is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA. He serves as Director of the Ahmanson-UCLA Cardiomyopathy Center, Co-Director of UCLA's Preventative Cardiology Program, and Clinical Co-Chief of Cardiology, UCLA Division of Cardiology. He attained the rank of Professor of Medicine, Geffen School of Medicine at UCLA in 2003. His research interests center on acute and chronic heart failure, preventative cardiology, quality of care, outcomes, and implementing treatment systems to improve clinical outcome. Dr. Fonarow has published over 600 research studies and clinical trials in heart failure, disease management, preventative cardiology, and outcomes research. New therapies and management strategies for advanced heart failure and research into the pathophysiology of this disease are conducted at UCLA under his direction. He has also developed and successfully implemented a comprehensive atherosclerosis treatment program at the UCLA Medical Center (Cardiovascular Hospitalization Atherosclerosis Management Program: CHAMP), which served as the model for the American Heart Association's Get With The Guidelines Program. Dr. Fonarow is a past chair of the steering committee for AHA Get With The Guideline's Program and the ACC ACTION Registry-GWTG. He also chaired ADHERE, OPTIMIZE-HF, and IMPROVE-HF performance improvement registries. He is on the steering committee and serves as an investigator for a number of ongoing randomized clinical trials in heart failure. He serves as a reviewer and serves on the editorial boards for a number of leading cardiovascular journals. Dr. Fonarow received the outstanding UCLA Cardiology Faculty Teaching Award in 1997 and was honored by the American College of Cardiology with the W. Proctor Harvey Young Teacher Award in 1998. He received an AHA Award of Meritorious Achievement in 2004. In 2009, he received the Raymond D. Bahr Award of Excellence and the Turning Guidelines into Lifelines Award from the AHA. In 2014, Dr. Fonarow was selected by Thomson Reuters for the list of Highly Cited Researchers, which identifies the world's most influential contemporary researchers across 21 scientific fields with the greatest number of published articles that received marks for exceptional impact. In 2015, Dr. Fonarow received a Clinical Research Forum Distinguished Clinical Achievement Award.
Barry Greenberg, MD
Barry Greenberg, MD
Distinguished Professor of Medicine Director,
Advanced Heart Failure Treatment Program
Department of Medicine/Cardiology
University of California, San Diego
San Diego, CA
Bio
Dr. Greenberg, director of the Advanced Heart Failure Treatment Program, is a leading cardiologist specializing in heart failure. He is a founding member and past president of the Heart Failure Society of America (HFSA). He has been consistently selected as one of the "Best Doctors in America" since 1995.
Dr. Greenberg has been working in cardiology since 1971, including positions at the National Heart, Lung and Blood Institute (NHLBI), Oregon Health Sciences University, Royal Postgraduate Medical College, Hammersmith Hospital in London, and College de France in Paris.
Dr. Greenberg has been at UC San Diego since 1995, and is currently Professor of Medicine at UC San Diego School of Medicine and Director, Advanced Heart Failure Treatment Program at UC San Diego.
In addition to his clinical activities, Dr. Greenberg leads an active research program investigating basic mechanisms involved in heart failure and the development of new drugs and strategies to treat patients with this condition. He serves on the editorial boards of numerous cardiology journals and is an associate editor of the Journal of the American College of Cardiology.
Dr. Greenberg considers it a great privilege to get to know and help his patients and their families.
Mariell Jessup, MD
Mariell Jessup, MD
Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA
Bio
Dr. Jessup, who is board certified in Internal Medicine, Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology, is Professor of Medicine at the University of Pennsylvania School of Medicine, Associate Chief-Clinical Affairs, Cardiovascular Division of Medicine, and Medical Director of the Heart and Vascular Center at Penn Medicine, where she works with a multi-disciplinary team of cardiologists, cardiac and vascular surgeons, nurse practitioners, and nurses to deliver collaborative, cutting-edge care to patients. Dr. Jessup’s focus throughout her career has been on the optimal management of patients with heart failure, including the appropriate selection of patients for heart transplant or ventricular assist devices.
She has been a member of the committee to revise ACC/AHA Guidelines for the Management of Heart Failure, published in 2001 and most recently in 2005. She was the Chair of the ACC/AHA Guidelines focused update for heart failure published in March, 2009. She is now the Vice-Chair of that same committee. Dr. Jessup served on the American Heart Association’s Council of Clinical Cardiology Program Committee, and was a member-at-large on the AHA annual meeting’s program committee. She served for two years as the Chair of the Committee for Scientific Sessions Program of the AHA. She is a member of the Board of Directors of the national AHA and became President of the American Heart Association in June of 2013. She completed a 4-year term as an ABIM representative for the Residency Review Committee-Internal Medicine of the ACGME, and a 6-year term on the ABIM’s Cardiovascular Board. Dr. Jessup is currently the Chair of ABIM’s Cardiovascular Specialty Board. She joined the inaugural Board of the Advanced Heart Failure and Transplant cardiology secondary subspecialty, and served as Chair from June 2012 to 2014. She served as the Co-chairman of the ISHLT’s Heart Failure Council, and served on the Board of Directors of the ISHLT for three years. She was a member of the Executive Council of the Heart Failure Society of America, and served as the secretary for the HFSA. She is on the Steering committee of the INTERMACs registry for ventricular assist devices.
Dr. Jessup has published numerous articles as well as editorials, reviews, chapters and reports from committees on heart failure, as well as heart transplant. She has been recognized by The Best Doctors in America and in Philadelphia Magazine’s Top Docs issue.
Dr. Jessup received her Bachelor of Arts degree from the University of Pennsylvania and a medical degree from Hahnemann Medical College in Philadelphia. She completed her residency in internal medicine at Hahnemann University Hospital and a cardiovascular fellowship at the Hospital of the University of Pennsylvania.
| 1. | Describe the pathophysiology and impact of heart rate on heart failure morbidity and mortality in patients with systolic heart failure. | 2. | Implement current optimal medical therapy for the treatment of chronic congestive heart failure |
| 3. | Discuss the role of vasoactive peptides and If channel in the regulation of the cardiovascular system | 4. | Assess current data and potential role of new and emerging therapies for the treatment of heart failure with reduced ejection fraction |
| 1. | Describe the pathophysiology and impact of heart rate on heart failure morbidity and mortality in patients with systolic heart failure. |
| 2. | Implement current optimal medical therapy for the treatment of chronic congestive heart failure |
| 3. | Discuss the role of vasoactive peptides and If channel in the regulation of the cardiovascular system |
| 4. | Assess current data and potential role of new and emerging therapies for the treatment of heart failure with reduced ejection fraction |
LAUNCH DATE/EXPIRATION DATE
This activity was launched on December 29, 2015 and will expire on December 29, 2016.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of cardiologists and internists with a sub-specialty in cardiology, primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with heart failure.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of cardiologists and internists with a sub-specialty in cardiology, primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with heart failure.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.5 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Gregg Fonarow, MD, FACC, FAHA | Dr. Fonarow has consulted for Amgen, Janssen, Medtronic, and Novartis and has received research grants from National Institutes of Health (NIH) and Medtronic. |
| Mariell Jessup, MD | Dr. Jessup does not have any financial relationships with any entity marketing, selling, or producing health care goods or services. |
| Barry Greenberg, MD | Dr. Greenberg has served as a consultant for Novartis, Teva, and Johnson and Johnson. |
HORIZON PLANNER DISCLOSURES
The following Horizon CME planners and managers, Brian Lee, PharmD, Cara Williams, PharmD, and Elizabeth Wilkerson hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
SUPPORTER ACKNOWLEDGEMENT
This activity is supported by educational funding provided by Amgen.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
